Active Ingredient History

  • Now
Arbaclofen placarbil is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.   Wikipedia

  • SMILES: NC[C@H](CC(=O)O)c1ccc(Cl)cc1
  • Mol. Mass: 213.66
  • ALogP: 1.86
  • ChEMBL Molecule:
More Chemistry
arbaclofen | arbaclofen hydrochloride | (r)-4-amino-3-(4-chlorophenyl)butan­oic acid | (r)-baclofen | stx209


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue